BSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
NSE Live
Mar 11, 15:56Prev. Close
20.06
Open Price
19.66
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Balaxi Pharmaceuticals (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 10.00 | 3.04 | 3.04 | 3.04 | 3.04 | |
| Total Share Capital | 10.00 | 3.04 | 3.04 | 3.04 | 3.04 | |
| Reserves and Surplus | 18.11 | 0.48 | -1.49 | -0.68 | 0.11 | |
| Total Reserves and Surplus | 18.11 | 0.48 | -1.49 | -0.68 | 0.11 | |
| Total Shareholders Funds | 28.11 | 3.52 | 1.55 | 2.36 | 3.15 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | |
| Trade Payables | 6.91 | 2.08 | 0.09 | 0.00 | 0.00 | |
| Other Current Liabilities | 0.46 | 0.51 | 0.04 | 0.03 | 0.03 | |
| Short Term Provisions | 2.41 | 0.00 | 0.00 | 0.18 | 0.18 | |
| Total Current Liabilities | 9.79 | 2.59 | 0.13 | 0.22 | 0.42 | |
| Total Capital And Liabilities | 37.91 | 6.11 | 1.69 | 2.58 | 3.57 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 0.19 | 0.01 | 0.01 | 0.00 | 0.00 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 0.19 | 0.01 | 0.01 | 0.00 | 0.00 | |
| Non-Current Investments | 0.10 | 0.00 | 0.00 | 0.00 | 3.27 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.92 | 0.32 | 0.03 | 0.00 | 0.00 | |
| Total Non-Current Assets | 1.21 | 0.33 | 0.04 | 0.04 | 3.31 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Inventories | 0.83 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade Receivables | 31.22 | 5.47 | 0.00 | 0.00 | 0.00 | |
| Cash And Cash Equivalents | 3.57 | 0.13 | 1.65 | 2.30 | 0.01 | |
| Short Term Loans And Advances | 1.08 | 0.17 | 0.00 | 0.00 | 0.00 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | 0.23 | 0.23 | |
| Total Current Assets | 36.70 | 5.78 | 1.65 | 2.54 | 0.26 | |
| Total Assets | 37.91 | 6.11 | 1.69 | 2.58 | 3.57 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | 0.00 | -- | -- | |
| Non-Current Investments Unquoted Book Value | 0.10 | -- | -- | 0.00 | 3.27 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | 0.01 |
11.03.2026
10.03.2026
ANG Lifescience Consolidated December 2025 Net Sales at Rs 18.73 crore, down 24.25% Y-o-Y
10.03.2026
05.03.2026
Everest Organic Standalone December 2025 Net Sales at Rs 42.59 crore, up 1.29% Y-o-Y
29.01.2026
Balaxi Pharma Consolidated December 2025 Net Sales at Rs 72.54 crore, down 1.02% Y-o-Y
29.01.2026
Balaxi Pharma Standalone December 2025 Net Sales at Rs 24.59 crore, up 120.41% Y-o-Y
19.11.2025
Balaxi Pharma Consolidated September 2025 Net Sales at Rs 56.18 crore, down 27.41% Y-o-Y
18.11.2025
Balaxi Pharma Standalone September 2025 Net Sales at Rs 19.31 crore, down 8.72% Y-o-Y
29.01.2026
Balaxi Pharma Consolidated December 2025 Net Sales at Rs 72.54 crore, down 1.02% Y-o-Y
29.01.2026
Balaxi Pharma Standalone December 2025 Net Sales at Rs 24.59 crore, up 120.41% Y-o-Y
19.11.2025
Balaxi Pharma Consolidated September 2025 Net Sales at Rs 56.18 crore, down 27.41% Y-o-Y
18.11.2025
Balaxi Pharma Standalone September 2025 Net Sales at Rs 19.31 crore, down 8.72% Y-o-Y
02.05.2024
09.04.2024
02.11.2023
03.08.2023
Adani Enterprises Q1 results: Net profit up 44% at Rs 674 crore, revenue down 38%
02.05.2024
09.04.2024
02.11.2023
03.08.2023
Adani Enterprises Q1 results: Net profit up 44% at Rs 674 crore, revenue down 38%
11.12.2020
25.10.2019
10.04.2019
21.02.2019
Shaily Engineering Plastics: A disappointing Q3, but don’t overlook its long-term prospects